Natera Stock Forecast, Price & News

Natera (NASDAQ:NTRA) Frequently Asked Questions

Is Natera a buy right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Natera in the last year. There are currently 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Natera stock.
View analyst ratings for Natera or view top-rated stocks.

How has Natera's stock price been impacted by COVID-19 (Coronavirus)?

Natera's stock was trading at $31.02 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NTRA stock has increased by 179.0% and is now trading at $86.56.
View which stocks have been most impacted by COVID-19.

When is Natera's next earnings date?

Natera is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Natera.

How were Natera's earnings last quarter?

Natera, Inc. (NASDAQ:NTRA) posted its quarterly earnings data on Thursday, November, 4th. The medical research company reported ($1.63) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.27) by $0.36. The medical research company earned $158.10 million during the quarter, compared to analyst estimates of $151.92 million. Natera had a negative trailing twelve-month return on equity of 85.05% and a negative net margin of 72.15%. The company's revenue for the quarter was up 61.2% on a year-over-year basis. During the same quarter last year, the business posted ($0.72) EPS.
View Natera's earnings history.

What guidance has Natera issued on next quarter's earnings?

Natera updated its FY 2021 earnings guidance on Thursday, December, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $615 million-$625 million, compared to the consensus revenue estimate of $614.70 million.

What price target have analysts set for NTRA?

12 Wall Street analysts have issued twelve-month target prices for Natera's shares. Their forecasts range from $129.00 to $160.00. On average, they anticipate Natera's stock price to reach $146.64 in the next year. This suggests a possible upside of 69.4% from the stock's current price.
View analysts' price targets for Natera or view top-rated stocks among Wall Street analysts.

Who are Natera's key executives?

Natera's management team includes the following people:

• Stephen Chapman, President, Chief Executive Officer & Director
• Robert A. Schueren, Chief Operating Officer (LinkedIn Profile)
• Michael Burkes Brophy, Chief Financial Officer (LinkedIn Profile)
• Paul R. Billings, Chief Medical Officer & Senior VP-Medical Affairs
• Eric A. Evans, Chief Scientific Officer

What is Steve Chapman's approval rating as Natera's CEO?

158 employees have rated Natera CEO Steve Chapman on Glassdoor.com. Steve Chapman has an approval rating of 91% among Natera's employees. This puts Steve Chapman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Natera's key competitors?

Some companies that are related to Natera include Laboratory Co. of America (LH), Quest Diagnostics (DGX), Guardant Health (GH), Elekta AB (publ) (EKTAY), Invitae (NVTA), Veracyte (VCYT), Fulgent Genetics (FLGT), CareDx (CDNA), RadNet (RDNT), Burning Rock Biotech (BNR), Castle Biosciences (CSTL), Genetron (GTH), Renalytix AI (RNLX), Personalis (PSNL) and DermTech (DMTK).
View all of NTRA's competitors.

What other stocks do shareholders of Natera own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Natera investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Transocean (RIG) and Allergan (AGN).

When did Natera IPO?

(NTRA) raised $101 million in an initial public offering (IPO) on Thursday, July 2nd 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.

What is Natera's stock symbol?

Natera trades on the NASDAQ under the ticker symbol "NTRA."

Who are Natera's major shareholders?

Natera's stock is owned by a variety of institutional and retail investors. Top institutional investors include Invesco Ltd. (3.23%), RTW Investments LP (1.97%), Marshall Wace LLP (1.44%), Farallon Capital Management LLC (1.37%), American Century Companies Inc. (1.28%) and Millennium Management LLC (1.26%). Company insiders that own Natera stock include Daniel Rabinowitz, Gail Boxer Marcus, Herm Rosenman, James Healy, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Patrick J Donovan, Robert Alan Schueren, Roelof Botha, Rowan E Chapman, Roy D Baynes, Steven Leonard Chapman, Todd C Cozzens and Todd C Cozzens.
View institutional ownership trends for Natera.

Which institutional investors are selling Natera stock?

NTRA stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Millennium Management LLC, Macquarie Group Ltd., Two Sigma Advisers LP, Balyasny Asset Management LLC, Balyasny Asset Management LLC, Frontier Capital Management Co. LLC, and Kornitzer Capital Management Inc. KS. Company insiders that have sold Natera company stock in the last year include Daniel Rabinowitz, Herm Rosenman, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Robert Alan Schueren, Roelof Botha, Rowan E Chapman, Steven Leonard Chapman, and Todd C Cozzens.
View insider buying and selling activity for Natera or view top insider-selling stocks.

Which institutional investors are buying Natera stock?

NTRA stock was bought by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Invesco Ltd., Bamco Inc. NY, Point72 Asset Management L.P., Janus Henderson Group PLC, Suvretta Capital Management LLC, Allianz Asset Management GmbH, and Deutsche Bank AG. Company insiders that have bought Natera stock in the last two years include James Healy, and Patrick J Donovan.
View insider buying and selling activity for Natera or or view top insider-buying stocks.

How do I buy shares of Natera?

Shares of NTRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Natera's stock price today?

One share of NTRA stock can currently be purchased for approximately $86.56.

How much money does Natera make?

Natera has a market capitalization of $8.19 billion and generates $391.01 million in revenue each year. The medical research company earns $-229.74 million in net income (profit) each year or ($4.58) on an earnings per share basis.

How many employees does Natera have?

Natera employs 1,815 workers across the globe.

What is Natera's official website?

The official website for Natera is www.natera.com.

Where are Natera's headquarters?

Natera is headquartered at 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070.

How can I contact Natera?

Natera's mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The medical research company can be reached via phone at (650) 249-9090 or via email at [email protected].